Stratec (SBS) Stock Price, News & Analysis

Company Overview

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

Key Stats

• Today's Range: €24.70 to €25.45
• 50-Day Range: €24.95 to €36.60
• 52-Week Range: €36.00 to €49.65
• Volume: 10,207 shs
• Average Volume: 6,253 shs
• Market Capitalization: $305.75 million
• P/E Ratio: 30.54
• Dividend Yield: 2.16%
• Price Target: N/A
• Consensus Rating: N/A

SBS Stock Analysis - Frequently Asked Questions

How have SBS shares performed this year?

Stratec's stock was trading at €29.80 on January 1st, 2025. Since then, SBS stock has decreased by 14.6% and is now trading at €25.45.
View the best growth stocks for 2025 here.

What other stocks do shareholders of Stratec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stratec investors own include Great Portland Estates (GPOR), Gogo (GOGO), Depomed (DEPO), Cenovus Energy (CVE), China Hydroelectric Corp Foreign (CHC), Bio-Rad Laboratories (BIO) and Berkshire Hills Bancorp (BHLB).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Utilities
• Current Symbol: ETR:SBS
• CIK: N/A
• Web: www.stratec.com
• Phone: +49-7082-79160
• Fax: N/A
• Employees: 1,464
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): €0.83
• Trailing P/E Ratio: 30.54
• Forward P/E Ratio: 7.07
• P/E Growth: 10.43
• Net Income: $9.89 million
• Net Margins: 4.00%
• Pretax Margin: N/A
• Return on Equity: 4.36%
• Return on Assets: 4.09%

Debt

• Debt-to-Equity Ratio: 66.97
• Current Ratio: 2.52
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $247.60 million
• Price / Sales: 1.23
• Cash Flow: €1.07 per share
• Price / Cash Flow: 23.85
• Book Value: €18.74 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 12,013,727
• Free Float: N/A
• Market Cap: $305.75 million
• Optionable: Not Optionable
• Beta: 0.16